F. Aubin

ORCID: 0000-0002-1421-4996
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Psoriasis: Treatment and Pathogenesis
  • Cancer Immunotherapy and Biomarkers
  • Dermatology and Skin Diseases
  • Cutaneous Melanoma Detection and Management
  • Polyomavirus and related diseases
  • Cervical Cancer and HPV Research
  • Cutaneous lymphoproliferative disorders research
  • Autoimmune Bullous Skin Diseases
  • CAR-T cell therapy research
  • Urticaria and Related Conditions
  • Nonmelanoma Skin Cancer Studies
  • Melanoma and MAPK Pathways
  • Skin Protection and Aging
  • Immunotherapy and Immune Responses
  • Colorectal Cancer Treatments and Studies
  • Autoimmune and Inflammatory Disorders
  • Genital Health and Disease
  • Allergic Rhinitis and Sensitization
  • Nail Diseases and Treatments
  • Full-Duplex Wireless Communications
  • Antenna Design and Analysis
  • Contact Dermatitis and Allergies
  • Colorectal and Anal Carcinomas
  • Hidradenitis Suppurativa and Treatments
  • Drug-Induced Adverse Reactions

Inserm
2015-2025

Université de franche-comté
2016-2025

Centre Hospitalier Universitaire de Besançon
2016-2025

Methodology and Quality of Life Unit in Oncology
2005-2025

Institut Pluridisciplinaire Hubert Curien
2024-2025

Centre Hospitalier de l’Université de Montréal
2014-2025

Établissement Français du Sang
2001-2024

Laboratoire Pacte
2022-2024

Centre Hospitalier Universitaire de Rennes
2014-2024

Groupe de Recherche sur le Psoriasis
2021-2024

Gravitational waves enable tests of general relativity in the highly dynamical and strong-field regime. Using events detected by LIGO-Virgo up to 1 October 2019, we evaluate consistency data with predictions from theory. We first establish that residuals best-fit waveform are consistent detector noise, low- high-frequency parts signals agreement. then consider parametrized modifications varying post-Newtonian phenomenological coefficients, improving past constraints factors ${\sim}2$; also...

10.1103/physrevd.103.122002 article EN publisher-specific-oa Physical review. D/Physical review. D. 2021-06-15
Corine Bertolotto Fabienne Lesueur Sandy Giuliano Thomas Strub Mahaut de Lichy and 94 more Karine Bille Philippe Dessen Benoit d’Hayer Hamida Mohamdi Audrey Remenieras E. Maubec Arnaud de la Fouchardière Vincent Molinié P. Vabres Stéphane Dalle Nicolas Poulalhon Tanguy Martin‐Denavit L. Thomas Pascale Andry-Benzaquen N. Dupin F. Boitier Annick Rossi Jean‐Luc Perrot B. Labeille Caroline Robert Bernard Escudier Olivier Caron Laurence Brugières Simon Saule Betty Gardie Sophie Gad Richard J. Kahnoski Jérôme Couturier Bin Tean Teh Paola Ghiorzo Lorenza Pastorino Susana Puig Célia Bádenas Håkan Olsson Christian Ingvar Etienne Rouleau Rosette Lidereau Philippe Bahadoran Philippe Vielh Eve Corda Hélène Blanché Diana Zélénika Pilar Galán F. Aubin Bertrand Bachollet Céline Becuwe Pascaline Berthet Yves Jean Bignon Valérie Bonadona Jean‐Louis Bonafé Marie‐Noëlle Bonnet‐Dupeyron F. Cambazard J. Chevrant‐Breton Isabelle Coupier S. Dalac Liliane Demange M. D’Incan Catherine Dugast Laurence Faivre Lynda Vincent-Fétita Marion Gauthier-Villars Brigitte Gilbert Florent Grange Jean‐Jacques Grob Philippe Humbert Nicolas Janin Pascal Joly Delphine Kérob Christine Lasset Dominique Leroux J. Levang Jean–Marc Limacher C. Bulaï Livideanu Michel Longy Alain Lortholary Dominique Stoppa-Lyonnet S. Mansard L Mansuy Karine Marrou Christine Matéus Christine Maugard Nicolás Meyer Catherine Noguès P Souteyrand Laurence Venat‐Bouvet Hélène Zattara Valérie Chaudru Gilbert Lenoir Mark Lathrop Irwin Davidson Marie-Françoise Avril Florence Démenais Robert Ballotti Brigitte Bressac–de Paillerets

10.1038/nature10539 article EN Nature 2011-10-18
Robin Kate Kelley Makoto Ueno Changhoon Yoo Richard S. Finn Junji Furuse and 95 more Zhenggang Ren Thomas Yau Heinz‐Josef Klümpen Stephen L. Chan Masato Ozaka Chris Verslype Mohamed Bouattour Joon Oh Park Olga Barajas Uwe Pelzer Juan W. Valle Li Yu Usha Malhotra Abby B. Siegel Julien Edeline Arndt Vogel Mehmet Akce Inmaculada Alés Díaz Gustavo R. Alves Sumitra Anand Çağatay Arslan Jamil Asselah Eric Assénat F. Aubin Li‐Yuan Bai Yuxian Bai Olga Barajas Susan E. Bates Stephen Begbie Irit Ben‐Aharon Nina Beri Marie‐Luise Berres Jean‐Frédéric Blanc Ivan Borbath Robert Bordonaro Mohamed Bouattour Giovanni Brandi Adam M. Burgoyne Kritiya Butthongkomvong Marcos Pedro Guedes Camandaroba Ke Cao Marcela Carballido Stephen L. Chan Jen‐Shi Chen Ming‐Huang Chen Xiaohong Chen Ashley Cheng Tai‐Jan Chiu Hye Jin Choi Hong Jae Chon Joëlle Collignon Antonio Cubillo Gracián S. Lindsey Davis Ricardo Saraiva de Carvalho D.J.A. de Groot Anne Demols Judith De Vos Maria Diab Jacob C. Easaw Martin Eatock Julien Edeline Rawad Elias Fredericus Eskens Alfredo Falcone Plinio Fernández Richard S. Finn Fábio Franke Masayuki Furukawa Junji Furuse Olumide B. Gbolahan Karen Geboes Keri-Lee Geneser Zhimin Geng Ravit Geva Roopinder Gillmore Thorsten Oliver Goetze Hongfeng Gou Julieta Grasselli Shanzhi Gu Mahmut Gümüş Nadia Haj Mohammad Chunyi Hao Hakan Harputluoğlu Hassan Hatoum Volker Heinemann Wang Kwong Ho Chiun Hsu Ayala Hubert Jun‐Eul Hwang Mevlüde İnanç Soledad Iseas Vaishnavi Jeyasingam Paula Jiménez Fonseca Warren Joubert Jitlada Juengsamarn

10.1016/s0140-6736(23)00727-4 article EN The Lancet 2023-04-16

<h3>Importance</h3> Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than those patients who are microsatellite-instability high (MSI-H). <h3>Objective</h3> To evaluate whether combining programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) improved patient survival metastatic CRC. <h3>Design, Setting, Participants</h3> A randomized phase 2 study was conducted 27 centers across Canada...

10.1001/jamaoncol.2020.0910 article EN cc-by JAMA Oncology 2020-05-07

Immune checkpoint inhibitors (ICIs) for cancer therapy frequently induce immune-related adverse effects (IRAEs). Therefore, most patients with preexisting autoimmune diseases have been excluded from clinical trials of ICIs. This study was undertaken to evaluate the safety and efficacy ICIs in disease cancer.A retrospective cohort conducted January 2017 2018 via 3 French national networks experts oncology autoimmunity. Adults who were receiving assessed occurrence flare disease, other IRAEs,...

10.1002/art.41068 article EN Arthritis & Rheumatology 2019-08-05

In the era of immunotherapies there is an urgent need to implement use circulating biomarkers in clinical practice facilitate personalized therapy and predict treatment response. We conducted a prospective study evaluate usefulness exosomal-PD-L1 melanoma patients' follow-up. studied dynamics from 100 patients by using enzyme-linked immunosorbent assay. found that PD-L1 was secreted through exosomes cells. Exosomes carrying had immunosuppressive properties since they were as efficient cancer...

10.1080/20013078.2019.1710899 article EN Journal of Extracellular Vesicles 2020-01-07

The gravitational-wave signal GW190521 is consistent with a binary black hole merger source at redshift 0.8 unusually high component masses, $85^{+21}_{-14}\,M_{\odot}$ and $66^{+17}_{-18}\,M_{\odot}$, compared to previously reported events, shows mild evidence for spin-induced orbital precession. primary falls in the mass gap predicted by (pulsational) pair-instability supernova theory, approximate range $65 - 120\,M_{\odot}$. probability that least one of holes 99.0%. final...

10.3847/2041-8213/aba493 article EN The Astrophysical Journal Letters 2020-09-01

Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given frequency of immune related adverse events and increasing use ICB, predictors response to CTLA-4 and/or PD-1 blockade represent unmet needs. Using a systems biology-based approach an assessment 779 paired blood tumor markers 37 stage III MMel patients, we analyzed association between parameters functional reactivity tumor-infiltrating cells after ex vivo...

10.1038/s41467-017-00608-2 article EN cc-by Nature Communications 2017-09-13
Thierry Conroy Florence Castan Anthony Lopez Anthony Turpin Méher Ben Abdelghani and 87 more Alice C. Wei Emmanuel Mitry James Biagi Ludovic Evesque Pascal Artru Thierry Lecomte Eric Assénat Lucile Bauguion Marc Ychou Olivier Bouché Laure Monard Aurélien Lambert Pascal Hammel Éric François Jean‐François Ramée H. Castanie Marc Pracht François Ghiringhelli Emmanuel Maillard Caroline Couffon Julien Volet Vincent Bourgeois Marion Chauvenet Jean‐Frédéric Blanc Denis Péré-Vergé Christelle De La Fouchardière Antoine Adenis Farid El Hajbi Jaafar Bennouna Patrick Texereau Roger Faroux Laurent Miglianico Christian Platini Jean-Louis Legoux François‐Xavier Caroli‐Bosc Karine Bouhier‐Leporrier Alice Gagnaire Victoire Granger Valérie Lebrun-Ly Rosine Guimbaud Yann Touchefeu Mohamed Gasmi Frédéric Di Fiore Jean François Seitz Pierre-Luc Etienne Catherine Poisson Yves Rinaldi Nabil Baba-Hamed Jean–Baptiste Bachet Thomas Aparicio Laurence Choné Marielle Guillet Julien Forestier Éric Terrebonne Mohamed Hebbar Gilles Breysacher Thierry André Faiza Khemissa-Akouz Vincent Hautefeuille Véronique Guerin‐Meyer Johannes Hartwig Y. Bécouarn David Malka Christophe Louvet Jean‐Luc Raoul L. Cany Beata Juzina C. Jouffroy Sophie Gourgou Mohammad Rassouli Haji Chalchal Daniel J. Renouf Ralph Wong Frédéric Lemay F. Aubin Félix Couture Elaine Mc Whirter Stephen Welch Petr Kavan B. Findlay C. Cripps Pablo Cano Shahid Ahmed Mohammed Harb Bryn Pressnail Scott Dowden Chris O’Callaghan

Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment modified FOLFIRINOX vs gemcitabine in patients resected pancreatic ductal adenocarcinoma; mature data are now available.To report 5-year outcomes and explore prognostic factors for overall survival.This open-label, phase was conducted 77 hospitals France Canada included aged 18 to 79 histologically confirmed adenocarcinoma who had undergone...

10.1001/jamaoncol.2022.3829 article EN JAMA Oncology 2022-09-01

PURPOSE To evaluate first-line pembrolizumab monotherapy efficacy and safety in patients with unresectable cutaneous squamous cell carcinomas (CSCCs). PATIENTS AND METHODS Patients, predominantly men, their CSSCs’ immunohistochemically determined programmed death-ligand 1 (PD-L1) status (tumor proportion score threshold, 1%), received (200 mg every 3 weeks). The primary endpoint was the 39-patient cohort’s objective response rate at week 15 (ORR W15 ). Secondary objectives were best ORR,...

10.1200/jco.19.03357 article EN Journal of Clinical Oncology 2020-07-30

A search for gravitational-wave signals produced by cosmic strings in the Advanced LIGO and Virgo full O3 data set improve upon previous LIGO-Virgo constraints on G\ensuremath{\mu} one to two orders of magnitude, depending model which is tested.

10.1103/physrevlett.126.241102 article EN publisher-specific-oa Physical Review Letters 2021-06-16

We report the observation of a coalescing compact binary with component masses $2.5\text{-}4.5~M_\odot$ and $1.2\text{-}2.0~M_\odot$ (all measurements quoted at 90% credible level). The gravitational-wave signal GW230529_181500 was observed during fourth observing run LIGO-Virgo-KAGRA detector network on 2023 May 29 by LIGO Livingston Observatory. primary source has mass less than $5~M_\odot$ 99% credibility. cannot definitively determine from data alone whether either is neutron star or...

10.3847/2041-8213/ad5beb preprint EN arXiv (Cornell University) 2024-04-05

Background— The Diabetes Atherosclerosis Intervention Study showed that treatment with fenofibrate decreases progression of coronary atherosclerosis in subjects type 2 diabetes. We determined whether on-treatment plasma lipid concentrations and LDL particle size contribute to the favorable effect on artery disease (CAD). Methods Results— A total 418 diabetes were randomly assigned 200 mg micronized daily or placebo. mean follow-up time was 39.6 months. peak diameter (LDL size) by...

10.1161/01.cir.0000057982.50167.6e article EN Circulation 2003-04-08

The efficacy of low doses certain neuroleptics in improving negative symptoms is still controversial. This study assessed the amisulpride, a benzamide which increases dopaminergic transmission at via presynaptic dopamine receptor blockade, on schizophrenia.The was designed as parallel-group, double-blind, placebo-controlled trial. Patients had to fulfil DSM-III criteria for schizophrenia, Andreasen's and have total score least 75 SANS; those treated with or antidepressants underwent six-week...

10.1192/bjp.166.1.68 article EN The British Journal of Psychiatry 1995-01-01

External acuminata condylomata (EAC) are among the most common sexually transmitted diseases. Although it is understood that low-risk human papillomavirus (HPV) genotypes 6 and 11 associated with EAC, there have only been a few, small, published studies reporting genotype-specific prevalence of HPV. The objective our study was to assess HPV for large number cases involving both men women evaluate potential benefit quadrivalent (genotypes 6, 11, 16, 18) vaccine in France.A total 256 260 who...

10.1086/590560 article EN Clinical Infectious Diseases 2008-07-18
Coming Soon ...